NCT05153187View on ClinicalTrials.gov

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

CompletedOBSERVATIONAL
Enrollment

1,170

Participants

Timeline

Start Date

August 31, 2019

Primary Completion Date

November 26, 2020

Study Completion Date

November 26, 2020

Conditions
Breast Cancer
Trial Locations (1)

Unknown

Pfizer Japan Inc., Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05153187 - Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan | Biotech Hunter | Biotech Hunter